Johnston SC, Ricks KM, Lakhal-Naouar I, Jay A, Subra C, Raymond JL, et al
This was compared to 80% in the Xtandi monotherapy arm and 71.4% in the leuprolide-only cohort
If you or someone close to you struggles with alcohol use, it may help to know that medication originally developed for diabetes and obesitysemaglutide or other glucagon-like peptide-1 (GLP-1) receptor agonistsmay one day become a treatment for alcohol use disorder (AUD)
Friedman SD, Baker LD, Borson S, et al
The goal is to become healthier, stronger, and metabolically more stable
The findings highlight a critical gap in current management strategies that rely solely on hormonal normalization, underscoring the need for more comprehensive care that addresses underlying metabolic dysfunction